2012 Annual Report - Prometic - Life Science, Inc.

More documents

Recommendations

Info

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (See governing statutes, nature of operations and going concern uncertainty - note 1) (In thousands of Canadian dollars except for per share amounts) Years ended December 31, <strong>2012</strong> 2011 Revenues (note 5) $23,321 $17,589 Expenses Costs of goods sold 5,326 1,854 Research and development expenses rechargeable 2,647 1,351 Research and development expenses non-rechargeable 7,663 9,879 Administration and marketing expenses 5,966 5,789 Loss on foreign exchange 116 140 Impairment of licenses and patents 49 68 Impairment of other investment (note 9) - 25 Loss on extinguishment of debt (note 18) 497 387 Finance costs (note 23) 1,483 1,363 Share of net profit of an associated company (note 10) (2) - Net loss ($424) ($3,267) Other comprehensive loss Change in unrealized exchange differences on translation of financial statements of foreign subsidiaries 48 (96) Total comprehensive loss ($376) ($3,363) Net loss attributable to: Owners of the parent 234 ($2,554) Non-controlling interests (658) (713) ($424) ($3,267) Total comprehensive loss attributable to: Owners of the parent $282 ($2,650) Non-controlling interests (658) (713) ($376) ($3,363) Earnings (Loss) per share Basic and diluted earnings (loss) per share attributable to the owners of the parent $0.00 ($0.01) Weighted average number of outstanding shares (in thousands) 421,073 373,635 For supplemental operations information, see note 23 The accompanying notes are an integral part of the consolidated financial statements. PROMETIC LIFE SCIENCES INC. 26
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY) (See governing statutes, nature of operations and going concern uncertainty - note 1) (In thousands of Canadian dollars) Contributed Surplus Foreign currency Future Non- Share Stock-based translation investment controlling Total capital compensation Warrants reserve rights Deficit Total interets deficiency $ $ $ $ $ $ $ $ $ Balance at January 1st, 2011 215,266 2,400 6,422 255 6,542 (243,438) (12,553) (914) (13,467) Loss for the year - - - - - (2,554) (2,554) (713) (3,267) Issuance of shares to non-controlling interest - - - - - - - 1,500 1,500 Foreign currency translation reserve - - - (96) - - (96) - (96) Share issue expenses - - - - - (59) (59) - (59) Stock-based compensation - 311 - - - - 311 - 311 Issuance of shares (note 20 a) 5,511 - - - - - 5,511 - 5,511 Issuance of warrants - - 999 - - - 999 - 999 Balance at December 31, 2011 220,777 2,711 7,421 159 6,542 (246,051) (8,441) (127) (8,568) Loss for the year - - - - - 234 234 (658) (424) Foreign currency translation reserve - - - 48 - - 48 - 48 Share issue expenses - - - - - (653) (653) - (653) Stock-based compensation - 505 - - - - 505 - 505 Issuance of shares (note 20 a) 3,964 - (56) - - - 3,908 - 3,908 Share capital to be issued (note 20 a) 9,822 - - - - - 9,822 - 9,822 Issuance of warrants - - 1,181 - - - 1,181 - 1,181 Balance at December 31, <strong>2012</strong> 234,563 3,216 8,546 207 6,542 (246,470) 6,604 (785) 5,819 The accompanying notes are an integral part of the consolidated financial statements. PROMETIC LIFE SCIENCES INC. 27
Page 1 and 2: ANNUAL REPORT 2012 We believe in ou
Page 3 and 4: We have + 14 + 28 applications and
Page 5 and 6: WHO WE ARE ProMetic Life Sciences I
Page 7 and 8: On May 15, 2012, ProMetic received
Page 9 and 10: alliance for the manufacturing of o
Page 11 and 12: PROMETIC’S BUSINESS IS ORGANIZED
Page 17 and 18: MANAGEMENT’S DISCUSSION & ANALYSI
Page 19 and 20: Although the Company achieved its f
Page 21 and 22: During the year ended December 31,
Page 23 and 24: FOURTH QUARTER The following inform
Page 25 and 26: Following a consulting agreement en
Page 27: CONSOLIDATED STATEMENTS OF FINANCIA
Page 31 and 32: NOTES TO CONSOLIDATED FINANCIAL STA
Page 33 and 34: The gain or loss arising on the dis
Page 35 and 36: n) Income taxes The Company uses th
Page 37 and 38: IFRS 12 Disclosure of Involvement w
Page 39 and 40: 11. CAPITAL ASSETS Leasehold Equipm
Page 41 and 42: 13. BANK AND OTHER LOANS 2012 2011
Page 43 and 44: (b) Other loans: 1) Loan for an ini
Page 45 and 46: purposes. Consequently, the loans w
Page 47 and 48: 2012 During the year ended December
Page 49 and 50: d) Stock-based compensation: The Co
Page 51 and 52: 22. CAPITAL DISCLOSURES December 31
Page 53 and 54: Fair value hierarchy Financial inst
Page 55 and 56: December 31, 2012 December 31, 2011
Page 57 and 58: The Company has tax losses which ar
Page 59 and 60: d) Acquisition of capital assets an
Page 61 and 62: On March 7, 2013, the share purchas
Page 63 and 64: CORPORATE INFORMATION HEADQUARTERS

2012 Annual Report - Prometic - Life Science, Inc.

Create successful ePaper yourself

Delete template?

Save as template?